These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38073468)

  • 1. A real-world assessment of healthcare costs associated with agitation in Alzheimer's dementia.
    Grossberg G; Urganus A; Schein J; Bungay R; Cloutier M; Gauthier-Loiselle M; Chan D; Guerin A; Aggarwal J
    J Med Econ; 2024; 27(1):99-108. PubMed ID: 38073468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System.
    Jones E; Aigbogun MS; Pike J; Berry M; Houle CR; Husbands J
    J Alzheimers Dis; 2021; 83(1):89-101. PubMed ID: 34250934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental Healthcare Utilization and Cost Burden of Comorbid Insomnia in Alzheimer's Disease Patients.
    Qureshi ZP; Thiel E; Nelson J; Khandker R
    J Alzheimers Dis; 2021; 83(4):1679-1690. PubMed ID: 34420974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
    Kirbach S; Simpson K; Nietert PJ; Mintzer J
    Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.
    Black CM; Fillit H; Xie L; Hu X; Kariburyo MF; Ambegaonkar BM; Baser O; Yuce H; Khandker RK
    J Alzheimers Dis; 2018; 61(1):185-193. PubMed ID: 29103033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer's disease in an administrative claims database.
    Nair R; Haynes VS; Siadaty M; Patel NC; Fleisher AS; Van Amerongen D; Witte MM; Downing AM; Fernandez LAH; Saundankar V; Ball DE
    BMC Geriatr; 2018 Oct; 18(1):243. PubMed ID: 30326851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural history of Alzheimer's disease: a brain bank study.
    Jost BC; Grossberg GT
    J Am Geriatr Soc; 1995 Nov; 43(11):1248-55. PubMed ID: 7594159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Institutionalization risk and costs associated with agitation in Alzheimer's disease.
    Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Guerin A; Hartry A; Baker RA; Duffy R; Gwin K; Sanon Aigbogun M
    Alzheimers Dement (N Y); 2019; 5():851-861. PubMed ID: 31799369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis.
    Aigbogun MS; Stellhorn R; Hartry A; Baker RA; Fillit H
    BMC Neurol; 2019 Feb; 19(1):33. PubMed ID: 30819136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
    Rabinowitz J; Katz IR; De Deyn PP; Brodaty H; Greenspan A; Davidson M
    J Clin Psychiatry; 2004 Oct; 65(10):1329-34. PubMed ID: 15491235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.
    Waters HC; Stellhorn R; Touya M; Fitzgerald H; Bhattacharjee S; Citrome L
    J Med Econ; 2023; 26(1):316-325. PubMed ID: 36780296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of agitation in long-term care residents with dementia in the United States.
    Fillit H; Aigbogun MS; Gagnon-Sanschagrin P; Cloutier M; Davidson M; Serra E; Guérin A; Baker RA; Houle CR; Grossberg G
    Int J Geriatr Psychiatry; 2021 Dec; 36(12):1959-1969. PubMed ID: 34286877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study.
    Morris S; Patel N; Baio G; Kelly L; Lewis-Holmes E; Omar RZ; Katona C; Cooper C; Livingston G
    BMJ Open; 2015 Mar; 5(3):e007382. PubMed ID: 25770235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
    Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's.
    Zhao Y; Kuo TC; Weir S; Kramer MS; Ash AS
    BMC Health Serv Res; 2008 May; 8():108. PubMed ID: 18498638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.